Abstract
Secreted protein acidic and rich in cysteine (SPARC) is an extracellular glycoprotein expressed in several solid cancers, including malignant gliomas, upon adoption of metastatic or invasive behaviors. SPARC expression in glioma cells promotes invasion and survival under stress, the latter process dependent on SPARC activation of AKT. Here we demonstrate that downregulation of SPARC expression with short interfering RNA (siRNA) in glioma cells decreased tumor cell survival and invasion. SPARC siRNA reduced the activating phosphorylation of AKT and two cytoplasmic kinases, focal adhesion kinase (FAK) and integrin-linked kinase (ILK). We determined the contributions of FAK and ILK to SPARC effects using SPARC protein and cell lines engineered to overexpress SPARC. SPARC activated FAK and ILK in glioma cells previously characterized as responsive to SPARC. Downregulation of either FAK or ILK expression inhibited SPARC-mediated AKT phosphorylation, and targeting both FAK and ILK attenuated AKT activation more potently than targeting either FAK or ILK alone. Decreased SPARC-mediated AKT activation correlated with a reduction in SPARC-dependent invasion and survival upon the downregulation of FAK and/or ILK expression. These data further demonstrate the role of SPARC in glioma tumor progression through the activation of intracellular kinases that may provide novel therapeutic targets for advanced cancers.
Similar content being viewed by others
Accession codes
Accessions
GenBank/EMBL/DDBJ
References
Alvarez MJ, Prada F, Salvatierra E, Bravo AI, Lutzky VP, Carbone C et al. (2005). Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Res 65: 5123–5132.
Barker TH, Baneyx G, Cardo-Vila M, Workman GA, Weaver M, Menon PM et al. (2005). SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J Biol Chem 280: 36483–36493.
Chicoine MR, Silbergeld DL . (1995). Assessment of brain tumor cell motility in vivo and in vitro. J Neurosurg 82: 615–622.
Datta SR, Brunet A, Greenberg ME . (1999). Cellular survival: a play in three Akts. Genes Dev 13: 2905–2927.
Framson PE, Sage EH . (2004). SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 92: 679–690.
Giese A, Bjerkvig R, Berens ME, Westphal M . (2003). Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21: 1624–1636.
Gradishar WJ . (2006). Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7: 1041–1053.
Hecker TP, Grammer JR, Gillespie GY, Stewart Jr J, Gladson CL . (2002). Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. Cancer Res 62: 2699–2707.
Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho JS, Fulford L et al. (2004). Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 64: 3037–3045.
Kenney J, Schmiedl U, Maravilla K, Starr F, Graham M, Spence A et al. (1992). Measurement of blood–brain barrier permeability in a tumor model using magnetic resonance imaging with gadolinium-DTPA. Magn Reson Med 27: 68–75.
Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, Engbring JA, Wang S et al. (2005). Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res 65: 7370–7377.
Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE et al. (1999). A public database for gene expression in human cancers. Cancer Res 59: 5403–5407.
Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernajovsky Y et al. (1997). Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 3: 171–176.
Mundlos S, Schwahn B, Reichert T, Zabel B . (1992). Distribution of osteonectin mRNA and protein during human embryonic and fetal development. J Histochem Cytochem 40: 283–291.
Obara S, Nakata M, Takeshima H, Katagiri H, Asano T, Oka Y et al. (2004). Integrin-linked kinase (ILK) regulation of the cell viability in PTEN mutant glioblastoma and in vitro inhibition by the specific COX-2 inhibitor NS-398. Cancer Lett 208: 115–122.
Rempel SA, Golembieski WA, Ge S, Lemke N, Elisevich K, Mikkelsen T et al. (1998). SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. J Neuropathol Exp Neurol 57: 1112–1121.
Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK et al. (2005). Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65: 4051–4058.
Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan CT, Bigner DD et al. (2003). Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 278: 15951–15957.
Schultz C, Lemke N, Ge S, Golembieski WA, Rempel SA . (2002). Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res 62: 6270–6277.
Shi Q, Bao S, Maxwell JA, Reese ED, Friedman HS, Bigner DD et al. (2004). Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem 279: 52200–52209.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987–996.
Troussard AA, Costello P, Yoganathan TN, Kumagai S, Roskelley CD, Dedhar S . (2000). The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9). Oncogene 19: 5444–5452.
Watkins G, Douglas-Jones A, Bryce R, Mansel RE, Jiang WG . (2005). Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 72: 267–272.
**e D, Yin D, Tong X, O'Kelly J, Mori A, Miller C et al. (2004). Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Cancer Res 64: 1987–1996.
Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS et al. (2001). SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159: 609–622.
Acknowledgements
We thank Michael Cook for technical support. J Rich is a Damon Runyon-Lilly Clinical Investigator and Kimmel Scholar and supported by the Damon Runyon Cancer Research Foundation, the Sidney Kimmel Foundation for Cancer Research, the Pediatric Brain Tumor Foundation of the United States, the Childhood Brain Tumor Foundation and the USPHS Grants NS047409, NS054276, CA 108786 and CA 116659. A Hjelmeland is a Paul Brazen/American Brain Tumor Association Fellow, and she is also supported by the Southeastern Brain Tumor Foundation.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Rights and permissions
About this article
Cite this article
Shi, Q., Bao, S., Song, L. et al. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene 26, 4084–4094 (2007). https://doi.org/10.1038/sj.onc.1210181
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210181
- Springer Nature Limited
Keywords
This article is cited by
-
CircRNA circ_POSTN promotes the malignancy of glioma by regulating the miR-433-3p/SPARC axis
Metabolic Brain Disease (2023)
-
The role of SPARC (secreted protein acidic and rich in cysteine) in the pathogenesis of obesity, type 2 diabetes, and non-alcoholic fatty liver disease
Journal of Physiology and Biochemistry (2023)
-
SPARC accelerates biliary tract cancer progression through CTGF-mediated tumor–stroma interactions: SPARC as a prognostic marker of survival after neoadjuvant therapy
Journal of Cancer Research and Clinical Oncology (2023)
-
Fibronectin mediates activation of stromal fibroblasts by SPARC in endometrial cancer cells
BMC Cancer (2021)
-
Role of Matricellular Proteins in Disorders of the Central Nervous System
Neurochemical Research (2017)